Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Gesine Bug,Andreas Burchert,E. M. Wagner,N Kröger,Tobias Berg,Saskia Güller,Stephan Metzelder,Andrea Wolf,S Hünecke,Peter Bader,Johannes Schetelig,Hubert Serve,Oliver G. Ottmann

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

2017

Gesine Bug
Andreas Burchert
E. M. Wagner
N Kröger
Tobias Berg
Saskia Güller
Stephan Metzelder
Andrea Wolf
S Hünecke
Peter Bader
Johannes Schetelig
Hubert Serve
Oliver G. Ottmann

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Keywords:

Cancer research
Lymphoma
Panobinostat
Leukemia
Apoptosis
Hematology
Stem cell
Transplantation
Haematopoiesis
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations